剑指2030年千亿美元市场 华熙生物以五星中试平台抢占产业先机

Core Insights - The Ministry of Industry and Information Technology has announced the first batch of "Biomanufacturing Pilot Capacity Construction Platform List," with Huaxi Biological Technology (Tianjin) Co., Ltd. being recognized for its leading synthetic biology pilot platform and awarded the highest "five-star" certification [1][2] - Huaxi Biological is one of only five companies in the country to receive this five-star rating, achieving the highest certification in three core areas: cosmetics, food additives, and biopharmaceuticals, marking a significant breakthrough in China's biomanufacturing infrastructure [1][2] Company Summary - Huaxi Biological's synthetic biology pilot transformation platform has a total investment exceeding 3 billion yuan, with a building area of 40,000 square meters and equipped with 64 pilot production lines [1] - The platform can simultaneously conduct large-scale transformation experiments for six categories of bioactive substances, serving multiple strategic emerging industries, including pharmaceuticals, health, and personal care [1] Industry Summary - The pilot platform is crucial for bridging the "valley of death" in the transformation of biomanufacturing research achievements, as China's technology achievement conversion rate is only about 10%, significantly lower than that of developed countries [1][2] - The platform innovatively creates a "cell factory" industrial debugging center, utilizing an intelligent central control system for real-time monitoring and early warning analysis of production processes, and employs a "flexible production line" design to quickly adapt to different pilot needs [2] - The establishment of this five-star certification is a significant signal of the national acceleration of biomanufacturing industry layout, with plans to cultivate over 20 biomanufacturing pilot platforms by 2027 [2]